Orexigen Therapeutics Inc. (OREX) is in the Pharma Industry

• Sort by
• View by Content Type

• Five Presentations from the Recent Biotech Investment Conference

  Mike Huckman submits: Medivation's Presentation: Standing Room Only A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer PFE, Medivation MDVN had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at yesterday's BioCentury/Thomson Reuters biotech investment conference...

  External links 2008-09-05

  Tags: Biotech, Healthcare, Amylin Pharmaceuticals Inc., Celgene Corp., Dendreon Corp., Eli Lilly & Co., Medivation Inc., Orexigen Therapeutics Inc., Pfizer Inc.

• Orexigen Therapeutics Q4 2007 Earnings Call Transcript

  Question-and-Answer Session Operator Operator Instructions The first question is from Mr. Tom McGahren of Merrill Lynch. Please go ahead, Mr. McGahren. Thomas McGahren - Merrill Lynch Graham and everyone there, will we see any presentations between now and the end of the year and could you tell...

  Earnings calls 2008-03-31

  Tags: Orexigen Therapeutics Inc.

• Speak with other shareholders about: (Nasdaq: OREX), (OTCBB: WWAT), (OTC: HSXI), and (OTC: PMRX) .

  M2 PRESSWIRE-24 May 2007-Stockwire.com: Speak with other shareholders about: (Nasdaq: OREX), (OTCBB: WWAT), (OTC: HSXI), and (OTC: PMRX) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:24052007 AUSTIN, TX - Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in...

  Research articles 2007-05-24

  Tags: British Petroleum Co plc, compensation, FINANCE, Investment, investor, Mr., Nasdaq Stock Market Inc., Orexigen Therapeutics Inc., shareholder, stock

• RealPennies.com : Turning Pennies into dollars: (Nasdaq: OREX), (OTCBB: WWAT), (Pink Sheets: HSXI), (Pink Sheets: PMRX).

  M2 PRESSWIRE-24 May 2007-RealPennies.com: RealPennies.com : Turning Pennies into dollars: (Nasdaq: OREX), (OTCBB: WWAT), (Pink Sheets: HSXI), (Pink Sheets: PMRX).C1994-2007 M2 COMMUNICATIONS LTD RDATE:24052007 Are you a public company looking for exposure? Contact RealPennies.com - 1.800.940.6559 For more...

  Research articles 2007-05-24

  Tags: British Petroleum Co plc, FINANCE, HEALTHCARE, investor, Manufacturing, Mr., Nasdaq Stock Market Inc., Orexigen Therapeutics Inc., SOFTWARE

Additional Resources

• Orexigen® Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates

  EmpaticTM Shows Long-Term Weight Loss, Improved Quality of Life; ContraveR Reduces Rate of Metabolic Syndrome by Half - Data Presented at The Obesity Society Annual Scientific Meeting Offer Hope to 75 Million Americans Considered Obese - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. ,...

  Articles 2008-10-06

• Orexigen® Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release Used in Contrave®

  - Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today presented data showing the investigational drug, ContraveR...

  Articles 2008-10-06

• Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

  -- Company Also Announces Participation in Upcoming Investor Conferences in October -- SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for October 2008,...

  Articles 2008-09-29

• Orexigen® Therapeutics to Present at Upcoming Investor Conferences

  SAN DIEGO -- Orexigen([R]) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences: Canaccord Adams Diabetes and Obesity ConferenceFriday, June 6, 2008, 1:20 P.M. Pacific timeHotel Nikko, San...

  Articles 2008-06-04

• Orexigen® Therapeutics to Present at Upcoming Investor Conferences

  SAN DIEGO -- Orexigen([R]) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences: [TABLE OMITTED]The 7th Annual JMP Securities Research ConferenceWednesday, May 21, 2008, 12:30 PM Pacific timeThe...

  Articles 2008-05-05

• OREXIGEN™ Therapeutics to Present at Upcoming Investor Conferences

  SAN DIEGO -- OrexigenTM Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences: Cowen and Company Health Care ConferenceMarch 17, 2008 1:45 p.m. - 2:20 p.m. Eastern TimeBoston...

  Articles 2008-03-12

• Orexigen Therapeutics Inc

  Orexigen Therapeutics Inc. said underwriters exercised options to purchase an additional 326,435 shares of common stock in connection with its initial public offering Jan. 23 when it raised a net of nearly $76 million. Send any news of locally based public companies to Mike Allen at mallen@sdbj. com....

  Articles 2008-02-25

• OREXIGEN™ Therapeutics to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

  SAN DIEGO -- Orexigen[TM] Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference. The conference is being held at the Grand Hyatt hotel...

  Articles 2008-01-31

• Orexigen Therapeutics Announces Pricing of Its Follow-on Offering

  SAN DIEGO -- OrexigenTM Therapeutics, Inc. (NASDAQ: OREX) today announced the public offering of 7,000,000 shares of common stock at a price of $11.00 per share. All shares are being offered by Orexigen. In addition, Orexigen has granted the underwriters a 30-day option to purchase an additional 1,050,000 shares to...

  Articles 2008-01-24

• Orexigen Therapeutics Announces Pricing of Its Follow-on Offering.

  M2 PRESSWIRE-24 January 2008-bellwetherreport.com: Orexigen Therapeutics Announces Pricing of Its Follow-on OfferingC1994-2008 M2 COMMUNICATIONS LTD RDATE:24012008 Today Bellwether Report has identified OrexigenTM Therapeutics Inc. (NASDAQ:OREX), a company that our analysts will be tracking over the ensuing weeks. They...

  Articles 2008-01-24

• OREXIGEN™ Therapeutics to Present Data Supporting Novel, PreClinical Drug Combination for Schizophrenia

  --Presentation Scheduled at the Society for Neuroscience Annual Meeting, NEUROSCIENCE 2007 in San Diego-- SAN DIEGO -- Orexigen[TM] Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced that the Company will be presenting at the Society for Neuroscience...

  Articles 2007-11-01

• Local biotech execs fly to New York City to make some news

  A slew of local biotechnology executives left the shores of San Diego for New York City last week to attend the 14th anniversary of NewsMakers in the Biotech Industry. Among the many firms that planned to showcase their technologies at the Millennium Broadway Hotel on Sept. 6 were...

  Articles 2007-09-10

• OREXIGEN™ Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference

  SAN DIEGO -- Orexigen[TM] Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced that Gary Tollefson, M.D., Ph.D., Orexigen's President and CEO, will present at the upcoming BioCentury NewsMakers in the Biotech Industry Conference on Thursday, September 6 at 11:25...

  Articles 2007-09-05

• OREXIGEN PRESENTS CONTRAVE CLINICAL REVIEW AT CBI.

  Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system CNS disorders including obesity, presented at The Center for Business Intelligence's CBI 3rd Annual Obesity Drug Development Summit. Ronald Landbloom, M.D., vice president of Medical and Regulatory Affairs at...

  Articles 2007-09-01

• Orexigen Therapeutics Inc

  Orexigen Therapeutics Inc. has announced the appointment of Heather Turner as vice president and general counsel. Turner joins Orexigen from Conor Medsystems LLC, where she served as associate general counsel corporate...

  Articles 2007-07-30

• Orexigen Therapeutics, Inc is Added to the Bellwether Watch list.

  M2 PRESSWIRE-25 June 2007-Biotech News: Orexigen Therapeutics, Inc is Added to the Bellwether Watch listC1994-2007 M2 COMMUNICATIONS LTD RDATE:25062007 Orexigen Therapeutics, Inc (NASDAQ:OREX) is Added to the Bellwether Watch list Orexigen Therapeutics, Inc. is a biopharmaceutical company focused ...

  Articles 2007-06-25